Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker for Gangliosidosis: BioGM1 / BioGM2 AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL

NCT02298647 is registered in ClinicalTrials.gov with CENTOGENE GmbH Rostock as lead sponsor.

NCT NCT02298647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02298647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker for Gangliosidosis: BioGM1 / BioGM2 AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL
Lead sponsor
CENTOGENE GmbH Rostock
Phase
Observational
Overall status
Withdrawn
Start date
August 20, 2018
Completion date
February 28, 2021
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

dysostosis multiplex, hepato-splenomegaly, mental retardation, seizures